Erythropoietin is a naturally occurring glycoprotein hormone produced mainly by the kidneys in response to reduced oxygen availability.

Its established physiological role is to support the survival and maturation of red-blood-cell precursors within bone marrow.

Researchers also reported protective effects of erythropoietin in experimental models involving nerves, heart, kidney, retina, skin and other tissues.

Using full erythropoietin for general tissue protection is problematic because sustained exposure can increase red-cell mass, blood viscosity and thrombotic risk.

ARA-290 was designed as a small non-erythropoietic mimetic that might retain selected repair-related signals without strongly activating classical erythropoiesis.

The generic international name cibinetide was subsequently assigned to the molecule.

Protein surfaces can bring amino-acid side chains close together even when those residues are not neighbours in the protein’s linear sequence.

Researchers identified a group of water-exposed residues around erythropoietin’s helix-B region that were proposed to contribute to tissue-protective activity.

They then linked an ordered set of selected residues into a short linear peptide called helix-B surface peptide.

The original sequence began with glutamine and was written QEQLERALNSS.

The first glutamine was found to cyclise spontaneously into pyroglutamate.

A stable version was therefore manufactured intentionally with N-terminal pyroglutamate. This version became pHBSP, ARA-290 or cibinetide.

In single-letter notation, pyroglutamate is sometimes represented by the letter Z or by the prefix pE.

A simplified representation may therefore appear as pE-E-Q-L-E-R-A-L-N-S-S.

The molecule contains no cysteine, meaning it does not require disulphide-bond formation.

It also contains no methionine, tryptophan or tyrosine residues that commonly create prominent oxidation pathways in some other research peptides.

Important degradation routes can still include glutamine or asparagine deamidation, terminal ring opening, peptide-bond hydrolysis and amino-acid epimerisation.

Pyroglutamate is a cyclic amino-acid residue formed when glutamine or glutamic acid closes into a five-membered ring.

The original HBSP peptide began with glutamine.

A proportion of that material converted spontaneously into pyroglutamate, creating inconsistent molecular forms.

Cibinetide was therefore produced with pyroglutamate already present at the first position.

The modification blocks the ordinary free N-terminal amino group and can reduce degradation by some aminopeptidases.

The Proposed Innate Repair Receptor

The proposed receptor is commonly described as involving an erythropoietin-receptor component and CD131.

CD131 is also known as the beta-common receptor because it contributes to receptor systems used by granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5.

The repair-receptor model proposes that tissue injury, hypoxia or inflammation increases local availability of the relevant receptor components.

Short exposure to cibinetide is then proposed to initiate intracellular survival and inflammation-resolving signals.

Downstream Signalling

Experimental studies describe pathways involving Janus kinases, STAT proteins, PI3K-Akt, MAP kinases and inhibition of selected NF-κB-related inflammatory responses.

These pathways are common to many cytokine and stress-response systems and are not uniquely diagnostic of cibinetide activity.

Proposed Biological Effects

Laboratory research reports reduced apoptosis, moderated inflammatory signalling, improved cell survival and support for repair processes.

In nerve models, the proposed effect includes reduced neuroinflammation and support for small-fibre regeneration.

Early genetic and functional experiments supported a role for CD131 in erythropoietin-related tissue protection.

This led to the proposed EPOR–CD131 heteroreceptor model.

Other investigators have questioned whether the two receptor components form a stable direct complex.

A 2018 study reported that erythropoietin did not promote detectable direct interaction between EPOR and the beta-common receptor in the tested systems.

Later commentary has continued to question whether CD131 is always required for protective erythropoietin signalling.

Functional cooperation, transient association, indirect pathway convergence and different receptor compositions remain possible explanations.

Reviews report an elimination half-life of approximately two minutes after intravenous exposure.

Following subcutaneous exposure, a human elimination half-life of approximately twenty minutes has been described.

These figures are route and study specific and should not be treated as universal product specifications.

A short plasma half-life does not necessarily mean that every intracellular response ends within minutes.

Receptor-triggered signalling, altered gene expression and repair processes can continue after the initiating peptide has been cleared.

Conversely, prolonged downstream effects cannot be assumed solely because a biological mechanism is theoretically possible.

Small sensory fibres transmit pain and temperature information.

Small autonomic fibres contribute to sweating, blood-pressure regulation, digestion, heart-rate responses and other involuntary functions.

Damage can produce burning pain, electric sensations, tingling, altered heat or cold perception, abnormal sweating and dizziness on standing.

Causes include diabetes, autoimmune disease, sarcoidosis, certain medicines, infections, inherited disorders and unknown factors.

Symptom-relieving medicines can reduce pain perception without restoring damaged nerve fibres.

Cibinetide attracted interest because animal and early human findings suggested both symptom changes and measurable differences in small nerve-fibre abundance.

Twenty-two people with sarcoidosis and symptoms consistent with small-fibre neuropathy entered the exploratory study.

Participants received cibinetide or placebo under a four-week controlled protocol.

The investigators assessed safety, neuropathic symptoms and quality-of-life measurements.

Patient-reported small-fibre-neuropathy symptoms improved more in the active-treatment group than in the placebo group.

The treatment appeared generally well tolerated within the short study.

The sample was too small to establish uncommon adverse effects, durable symptom control or broad effectiveness across different neuropathy causes.

The 28-day randomised study enrolled 64 people with sarcoidosis-associated small nerve-fibre loss and neuropathic pain.

Participants were assigned to placebo or one of several cibinetide exposure groups.

The primary endpoint was change in corneal nerve-fibre area measured through corneal confocal microscopy.

Corneal confocal microscopy provides a non-invasive image of small nerve fibres within the cornea.

Skin biopsies were also analysed for GAP-43-positive intraepidermal nerve fibres, a marker associated with regenerating fibres.

One treatment group showed a statistically significant placebo-corrected increase in corneal nerve-fibre area.

Increases in regenerating skin fibres were also reported.

Greater baseline pain was associated with stronger symptom responses in exploratory analyses.

Six-minute walking performance also changed in association with selected nerve-fibre measurements.

Chronic high glucose, abnormal lipid metabolism, inflammation and microvascular dysfunction can damage peripheral nerves.

Participants in the controlled study received cibinetide or placebo over a short treatment period.

Neuropathic symptoms measured with the PainDetect questionnaire improved significantly in the active group.

Participants with more abnormal baseline corneal nerve-fibre density showed an increase in density compared with no corresponding change in the placebo group.

Exploratory metabolic measurements also changed, leading investigators to propose that cibinetide might influence both neuropathy and metabolic control.

The study was not large or long enough to demonstrate prevention of foot ulceration, reduced amputation risk, sustained glucose control or durable neurological recovery.

The metabolic interpretation should also be separated from a retracted mouse paper that previously supported insulin-sensitivity claims.

Diabetic macular oedema occurs when fluid accumulates within the central retina and threatens detailed vision.

Nine participants entered the investigator-led study, and eight completed the twelve-week course.

There was no improvement in the group’s mean best-corrected visual acuity.

Mean central retinal thickness, central retinal sensitivity and tear production also did not improve.

A visual-function questionnaire showed a small improvement, and selected participants had changes in retinal thickness, metabolic measures or albuminuria.

No participant developed detectable anti-cibinetide antibodies during the study.

One participant experienced a clinically important decline in visual acuity and left the study to receive established treatment.

The absence of a control group, tiny sample and variable individual responses prevent reliable efficacy conclusions.

Thirty-six healthy participants received a single cibinetide exposure or placebo in a double-blind randomised design.

Researchers used cognitive tasks, emotional-processing tests and brain imaging to look for a pattern resembling early antidepressant effects.

Cibinetide altered selected measures of emotional processing.

The direction and strength of the findings did not provide an unequivocal antidepressant-like profile.

Healthy-volunteer emotional-processing tasks cannot establish symptom improvement in people with major depressive disorder.

No established cibinetide treatment programme for depression was identified.

Complex regional pain syndrome is a chronic pain condition that can involve sensory, autonomic, motor and inflammatory abnormalities.

A Dutch trial was registered to investigate cibinetide in adults with complex regional pain syndrome type one.

The European clinical-trials register continues to show the study without publicly posted results.

A registry entry establishes that a trial was planned or conducted. It does not establish positive efficacy.

Claims that ARA-290 is proven for complex regional pain syndrome therefore exceed the publicly available evidence.

Peripheral Nerve Injury

Rodent studies report reduced pain-like behaviour, altered microglial responses and support for sensory-nerve recovery.

Diabetic Nerve Damage

Experimental diabetic models have assessed autonomic and sensory nerve structure, neuritic dystrophy and inflammatory signalling.

Results have not been uniformly positive. One Akita-mouse experiment found no effect on ganglionic neuron number or continuing neuronopathy during the studied period.

Brain and Spinal Research

Models of stroke, traumatic injury, stress and neuroinflammation have reported protective signals.

Heart and Vascular Research

Experimental studies have investigated myocardial ischaemia, heart failure, endothelial function and atherosclerosis.

Kidney Research

ARA-290 has been tested in renal ischaemia, transplantation and inflammatory models.

At least one prominent acute-kidney-injury paper has now been retracted and should be excluded from supportive evidence summaries.

Skin and Wound Models

Diabetic wound models have examined re-epithelialisation, local inflammation, angiogenesis and repair strength.

Autoimmune and Transplant Research

Investigators have studied inflammatory disease and pancreatic-islet transplantation in animals.

Acute Kidney Injury Paper

A 2012 Molecular Medicine article reported that delayed pHBSP administration reduced renal injury in a rodent ischaemia-reperfusion model.

The journal retracted the article on 26 February 2026 following concerns involving similarities within published protein-blot images.

Its kidney-protection findings should not be cited as valid experimental proof.

Diet-Induced Insulin-Resistance Paper

A 2014 British Journal of Pharmacology article reported protection against diet-induced insulin resistance in mice.

The paper was formally retracted in 2024.

Online claims concerning fat loss, insulin sensitivity or metabolic protection sometimes continue to cite the original article without acknowledging the retraction.

• Clinical development has not progressed to an identified successful phase-three programme.
• No UK marketing authorisation was identified.
• No FDA marketing approval was identified.
• The principal neuropathy studies were short.
• Participant numbers were modest.
• Sarcoidosis-associated neuropathy may not represent other neuropathies.
• Corneal nerve measurements are surrogate endpoints.
• Corneal nerve change does not prove whole-body neurological recovery.
• GAP-43 staining suggests regeneration but does not prove restored function.
• Pain questionnaires remain subjective.
• Exploratory subgroup analyses can overestimate effects.
• The most effective exposure was not consistently dose dependent.
• Six-minute-walk performance has many possible influences.
• Long-term pain recurrence was not characterised adequately.
• Reduction in disability has not been established in a large trial.
• Prevention of foot ulceration has not been demonstrated.
• Prevention of amputation has not been demonstrated.
• Diabetic macular-oedema evidence was open label.
• The eye study enrolled only nine people.
• Mean visual acuity did not improve in the eye study.
• No clinical depression-treatment evidence was identified.
• Registered CRPS results were not publicly available.
• The proposed receptor model remains debated.
• Direct receptor-binding evidence is incomplete.
• Many preclinical indications have no corresponding human trial.
• At least two influential ARA-290 papers have been retracted.
• Publication bias may favour positive studies.
• Several studies involved developers or patent holders.
• Long-term immunogenicity is uncertain.
• Pregnancy safety is not established.
• Long-term cancer safety is not established.
• Research-market products may not contain authentic cibinetide.
• An ordinary HBSP peptide is not identical to pyroglutamate cibinetide.
• A high HPLC percentage cannot prove complete identity or sterile quality.

Short-Term Tolerability

Controlled neuropathy studies did not identify a consistent pattern of severe treatment-attributable toxicity.

Reported events included local reactions and isolated medical events that did not form a clear repeated safety signal.

Small studies cannot estimate risks occurring in one person per thousand or one person per ten thousand.

Antibody Formation

No anti-cibinetide antibodies were detected in the small diabetic macular-oedema study.

This does not exclude antibodies after longer exposure, different formulations or impurity-containing products.

Blood Pressure and Cardiovascular Effects

The clinical programme did not show the characteristic sustained haematocrit increase associated with therapeutic erythropoietin.

It remains inappropriate to claim that cardiovascular risk is zero.

Inflammation, endothelial signalling, autonomic function and product contamination could create risks independent of red-cell production.

Neurological Effects

The peptide was developed to influence nerve and repair signalling.

Long-term effects on pain processing, autonomic function, sensation and central nervous-system pathways remain incompletely characterised.

Erythropoietin binds a homodimeric erythropoietin receptor on red-cell progenitors and prevents their programmed cell death.

This increases red-blood-cell production and can raise haemoglobin and haematocrit.

ARA-290 does not reproduce the two major receptor-binding surfaces used by full erythropoietin to activate classical erythropoiesis.

Human clinical studies did not demonstrate a meaningful rise in red-cell measures attributable to cibinetide.

That finding is one of the central distinctions between ARA-290 and authorised erythropoietin medicines.

Immune Regulation

ARA-290 is proposed to reduce selected inflammatory signals rather than suppress the complete immune system.

The effect may differ according to tissue, disease stage and accompanying medicines.

Autoimmune Disease

Sarcoidosis provided a relevant inflammatory research setting.

Positive findings in one immune-mediated disorder do not establish benefit across rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease or other autoimmune conditions.

Infection

Inflammatory signalling contributes to both tissue injury and pathogen control.

Modifying this balance during infection has not been characterised adequately in large human studies.

Cancer

Anti-apoptotic and tissue-survival signalling is potentially relevant to malignant as well as healthy cells.

No reliable evidence establishes that cibinetide promotes cancer, but long-term safety in people with active or previous malignancy remains insufficiently studied.

Clinical studies excluded pregnancy or required pregnancy precautions.

Placental transfer, embryo-fetal effects, breastfeeding exposure and long-term developmental outcomes have not been established.

Paediatric safety and effectiveness have not been demonstrated through an authorised programme.

People with severe kidney disease, liver disease, active cancer, major infection or complex autoimmune treatment may have different exposure or risk.

A peptide described as non-erythropoietic should not be assumed safe during pregnancy or in medically vulnerable populations.

• Incorrect peptide entirely
• Ordinary HBSP substituted for cibinetide
• Uncyclised N-terminal glutamine
• Incorrect pyroglutamate identity
• Ring-opened N-terminal material
• Missing one or more amino-acid residues
• Incorrect amino-acid order
• D-amino-acid or epimerised impurities
• Incorrect C-terminal amidation
• Truncated peptide
• Deletion-sequence impurities
• Incomplete coupling products
• Glutamine deamidation
• Asparagine deamidation
• Peptide-bond hydrolysis
• Incorrect net peptide quantity
• Residual trifluoroacetate
• Undeclared acetate or other counterions
• Residual coupling reagents
• Residual scavengers
• Residual organic solvents
• Elemental contamination
• Peptide aggregates
• Incorrect pH after manufacture
• Unverified bacterial-endotoxin control
• Unverified sterile quality
• Visible or subvisible particles
• Loss of material during warm transport
• Certificate unrelated to the supplied batch
• Raw-powder certificate presented as finished-vial evidence

What Meaningful ARA-290 Documentation Should Include

• Cibinetide or ARA-290 identity
• Complete 11-residue sequence
• Confirmation of N-terminal pyroglutamate
• Confirmation of the free C-terminal acid
• Observed intact molecular mass
• Tandem-MS sequence evidence
• Net peptide-content assay
• Chromatographic purity
• Named and unknown impurity results
• Uncyclised-HBSP result
• Ring-opened-pyroglutamate result
• Deletion-sequence profile
• Truncation profile
• Deamidation results
• Epimerisation assessment where relevant
• Counterion identification
• Trifluoroacetate or acetate quantity
• Water-content result
• Residual-solvent results
• Residual synthesis-reagent results
• Aggregate and particle assessment
• Biological-potency result where relevant
• Bacterial-endotoxin result
• Sterility result for a finished injectable medicine
• Batch-specific stability evidence
• Container-closure compatibility
• Finished-product batch number
• Testing-laboratory identity
• Analytical methods and acceptance criteria
• A statement identifying tests not performed

Why “99% HPLC” Is Not Enough

HPLC area purity does not prove that the main peak begins with pyroglutamate.

It does not confirm the free C-terminal acid, amino-acid stereochemistry or net active quantity.

It does not establish functional potency, endotoxin control, sterile manufacture or pharmaceutical equivalence to the investigational clinical product.

A certificate for raw peptide does not establish the quality of a finished vial.

Medicinal-Product Classification

MHRA guidance states that a product may be medicinal where it is presented as preventing or treating disease.

A product may also be medicinal where it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.

Claims involving nerve regeneration, neuropathic-pain treatment, tissue protection or inflammatory-disease improvement are strongly medicinal in character.

“Research Use Only” Wording

A research disclaimer does not automatically prevent medicinal classification.

Regulators may consider the website, product name, testimonials, imagery, instructions, intended audience and overall presentation.

Advertising Restrictions

Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product unless the required marketing authorisation, registration or certificate is in force.

This section provides general regulatory education rather than legal advice.

The European Commission granted orphan designation for cibinetide in the treatment of sarcoidosis in 2013.

European orphan designation was also granted for prevention of graft loss in pancreatic-islet transplantation.

US regulatory substance records identify FDA orphan-drug references associated with cibinetide, including neuropathic pain in sarcoidosis.

Orphan designation can provide development incentives, regulatory assistance and potential market exclusivity following approval.

It does not demonstrate that quality, safety and efficacy have satisfied the standard required for marketing authorisation.

Section S0 prohibits pharmacologically active substances that are not addressed elsewhere and have no current approval by a governmental regulatory health authority for human therapeutic use.

Cibinetide remained an investigational, non-approved substance on the review date.

S0 may therefore be relevant even though ARA-290 is not named individually.

Its erythropoietin-derived design also means athletes should not assume that the absence of red-cell stimulation removes all anti-doping concerns.

A current product-specific assessment through UK Anti-Doping, Global DRO or the relevant international federation is required.

ARA-290 appears in Peptides UK catalogues as lyophilised powder, an acetate-associated product or an injectable-style research vial.

Common commercial claims include nerve regeneration, inflammation reduction, chronic-pain relief, improved glucose control, kidney protection, wound healing and accelerated recovery.

Some pages also place it within combinations involving BPC-157, TB-500, KPV or growth-hormone-related peptides.

No controlled evidence establishes the safety or effectiveness of these combinations.

Clinical studies used a defined investigational product under ethical approval, manufacturing controls and medical monitoring.

Online material may contain the wrong terminal form, incorrect quantity, unreported counterions, synthesis impurities, endotoxin or microbial contamination.

Clinical-trial findings cannot authenticate a product merely because its label says ARA-290.

• Is the substance identified as ARA-290 or cibinetide?
• Is it distinguished from erythropoietin?
• Is it distinguished from ordinary HBSP?
• Is the complete 11-residue sequence stated?
• Is N-terminal pyroglutamate confirmed?
• Is the C-terminal free acid confirmed?
• Was intact mass measured?
• Was tandem-MS sequence evidence provided?
• Were uncyclised forms quantified?
• Were deamidation products assessed?
• Was net peptide quantity measured?
• Was the counterion identified?
• Were aggregates and particles assessed?
• Was bacterial endotoxin tested?
• Was finished-product sterility demonstrated?
• Does the certificate match the finished batch?
• Was the study cellular, animal or human?
• Was the human trial randomised?
• Was it placebo controlled?
• How many participants completed it?
• How long did follow-up continue?
• Was the outcome pain, function or a surrogate marker?
• Was corneal nerve change interpreted cautiously?
• Was skin GAP-43 staining confirmed independently?
• Was the result replicated in another population?
• Was a subgroup finding presented as the main result?
• Were treatment developers involved in the study?
• Has the cited article been retracted?
• Is a kidney claim based on the retracted 2012 paper?
• Is a metabolic claim based on the retracted mouse study?
• Is sarcoidosis evidence being transferred to unrelated pain?
• Is a registry entry being presented as a positive result?
• Is orphan designation being presented as approval?
• Is an online vial being treated as equivalent to clinical material?
• Is the source selling the product it describes?

The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.

Medical Director and Clinical Reviewer

Dr Laura Geige

Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.

Read professional profile

Medical and Nutritional Sciences Reviewer

Dr Rimas Geiga

Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.

Read professional profile

Medical and Healthcare Reviewer

Dr Snieguole Geige

Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.

Read professional profile

Dermatology Reviewer

Dr Giedre Narkiene

Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.

Read professional profile

Medical and Gerontology Reviewer

Dr Veronika Matutyte

Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.

Read professional profile

Cosmetology and Skin Health Contributor

Livija Samušienė

Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.

Read professional profile